As the FDA and CDC announced earlier today, out of a plethora of caution, they have recommended an interruption in the use of the Johnson & Johnson vaccine, as they review data on six reported U.S. cases of a rare and serious type of blood clot in individuals received after the vaccination of Johnson & Johnson. The FDA and CDC will provide details later this morning during their briefing.
This announcement will not have a significant impact on our vaccination plan: Johnson & Johnson vaccine so far accounts for less than 5 percent of recorded gunshots in the United States. Based on the actions the president took earlier this year, the United States has secured enough doses of Pfizer and Moderna for 300 million Americans. Over the past few weeks, we have made more than 25 million doses of Pfizer and Moderna available each week, and this week we will actually be making 28 million doses of these vaccines available. That is more than enough stock to continue the current rate of vaccinations of 3 million shots per day and to reach the president’s goal of 200 million shots with his 100.de day at the office – and continue to reach every adult who wants to be vaccinated. We work closely with our state and federal partners to quickly reschedule anyone who is scheduled for a J&J vaccine for a Pfizer or Moderna vaccine.
###